pipeline expansion

Moderna stock rises after positive Phase 1 hantavirus vaccine data, with analysts raising price targets amid signs of mRNA platform diversification beyond COVID.

Eli Lilly's 56% revenue growth and 156% EPS surge in Q1 2026, driven by GLP-1 dominance and oral formulation expansion, signal continuing upside potential for investors.

Gibson Energy closes $400M Chauvin acquisition, gains crude gathering assets backing long-term contracts and plans capacity expansion to 45,000 bbl/d by 2026.

Teva Pharmaceutical beats Q1 earnings expectations and announces $700M Emalex acquisition plus share buyback, signaling confidence in specialty drug strategy and cost-cutting targets.

Snail Inc. (SNAL) jumped 18.49% after-hours to $0.90 on 'Survivor Mercs' v1.0 launch across major platforms and portfolio diversification announcements.

Gilead acquires Tubulis for $3.15 billion including milestones, adding HER2-targeting ovarian cancer candidate to oncology pipeline—second major deal in months.

Novartis acquires Excellergy for up to $2 billion to develop Exl-111, a next-generation anti-IgE allergy drug in Phase 1 trials, strengthening its immunology pipeline.

Moderna stock surges 70% in 2026 on vaccine and cancer therapy pipeline expansion, but $2.8B losses amid $1.9B revenue temper bullish sentiment.

Nasus Pharma reports positive Phase 2 data for NS002 intranasal epinephrine, planning pivotal study Q4 2026 with strong cash position through Q2 2027.

Tarsus Pharma stock surges 20% as insider sells shares for tax withholding. Strong XDEMVY sales growth and improving margins offset insider transaction.

Actuate Therapeutics plans to present at the Citizens Life Sciences Conference on March 10, advancing elraglusib tablet into Phase 1/2 oncology trials launching H2 2026.

Energy Transfer expects 9.2-11.7% EBITDA growth in 2026 from completed projects, oil prices, and AI data center demand, offering a 7.2% dividend yield with 3-5% annual increases.

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.

GSK acquires 35Pharma for $950M, adding pulmonary hypertension treatment HS235 to its pipeline. Move strengthens GSK's position in the growing $18B market.

Energy Transfer offers higher yield (7.01% vs 6.01%) and growth potential through pipeline expansion, positioning it as a stronger MLP investment than Enterprise Products Partners for 2026.

Energy Transfer generated record $8.2B in distributable cash flow, far exceeding its 7.2% dividend requirements. The midstream company projects 9-12% EBITDA growth in 2026.